10-Q: Calidi Biotherapeutics Reports Q3 Loss, Boosts Cash

Calidi Biotherapeutics reported a net loss of $16.0 million for the first nine months of 2025, a decrease from the prior year, while significantly increasing its cash position through multiple equity financings.

Summary

• Calidi Biotherapeutics, a clinical-stage biotechnology company, reported a net loss of $16.0 million for the nine months ended September 30, 2025, an improvement from a $18.1 million net loss in the same period of 2024.
• The net loss attributable to common stockholders for the nine months ended September 30, 2025, was $21.5 million, compared to $19.7 million in the prior year, primarily due to deemed dividends on warrants.
• Research and development expenses increased by 4% to $7.4 million for the nine months ended September 30, 2025, from $7.1 million in 2024.
• General and administrative expenses decreased by 21% to $8.4 million for the nine months ended September 30, 2025, from $10.7 million in 2024.
• Cash and restricted cash balance increased to $10.6 million as of September 30, 2025, from $2.1 million as of September 30, 2024.
• The company completed several financing activities, raising $12.7 million from public offerings, $3.5 million from a registered direct offering, and $4.1 million from a warrant inducement offer during the nine months ended September 30, 2025.
• A 1-for-12 reverse stock split was effected on August 4, 2025, following a 1-for-10 reverse stock split on July 15, 2024, with all share and per share amounts retrospectively restated.
• The company sold its 75% ownership interest in its majority-owned subsidiary, Nova Cell, on October 27, 2025, for a purchase price of $6.0 million, satisfied partly by debt cancellation ($1.2 million) and deferred consideration ($4.8 million), plus an ongoing royalty.
• CLD-201, a SuperNova investigational drug candidate, received Fast Track Designation from the U.S. Food and Drug Administration (FDA) in July 2025 for the treatment of soft tissue sarcoma.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including a 'going concern' warning and persistent operating losses, despite successful capital raises. While there are positive clinical developments like Fast Track Designation, the fundamental financial stability remains a major concern, indicating a high-risk investment.

Positives

• Net loss for the nine months ended September 30, 2025, improved to $16.0 million from $18.1 million in the prior year.
• General and administrative expenses decreased significantly by $2.3 million (21%) for the nine months ended September 30, 2025.
• Cash and restricted cash increased substantially to $10.6 million as of September 30, 2025, from $2.1 million in the prior year, indicating successful capital raising efforts.
• CLD-201 received Fast Track Designation from the FDA in July 2025 for soft tissue sarcoma, potentially accelerating its development and review.
• The company successfully raised significant capital through multiple public offerings and warrant exercises, providing liquidity for ongoing operations.

Negatives

• The company continues to experience recurring losses from operations and negative cash flows from operating activities, with an accumulated deficit of $137.6 million as of September 30, 2025.
• Management estimates substantial doubt about the company's ability to continue as a going concern within 12 months from the date of issuance of the financial statements.
• Research and development expenses increased by 4% to $7.4 million for the nine months ended September 30, 2025, indicating continued high burn rate for drug development.
• Net loss attributable to common stockholders increased to $21.5 million for the nine months ended September 30, 2025, from $19.7 million in 2024, primarily due to deemed dividends on warrants.
• The company's stock has undergone two reverse stock splits (1-for-10 in July 2024 and 1-for-12 in August 2025), which often indicates a low stock price and efforts to maintain listing compliance, potentially diluting existing shareholders.
• The company faces multiple legal proceedings, including claims of defamation, constructive discharge, and securities fraud, which could result in significant costs and reputational damage.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and negative cash flows, requiring additional funding.
• Inability to secure additional financing in a timely manner or on favorable terms could force delays, reductions, or termination of research and development programs or future commercialization efforts.
• Issuance of equity securities to raise additional funds may result in significant dilution for existing stockholders and new securities may have senior rights.
• The company's product candidates are subject to long development cycles, and there is no certainty of successful development, regulatory approval, or market acceptance.
• The company is exposed to risks common to early-stage biotechnology companies, including possible failure of preclinical studies or clinical trials, dependence on key personnel, and protection of proprietary technology.
• Changes in economic conditions, including rising interest rates, volatile equity capital markets, and geopolitical conflicts, may adversely affect operations and ability to raise capital.
• The company is involved in several legal proceedings, including claims from former officers and a securities fraud complaint, which could lead to unfavorable outcomes and material adverse effects on financial condition or results of operations.
• The sale or perception of a substantial number of common stock by selling securityholders could adversely affect the stock price and future financing capabilities.
• The company has significant future purchase commitments under manufacturing and supplier agreements totaling $0.3 million, and potential contingent payments under license agreements if milestones are met.

Future Outlook

The company expects to continue incurring significant and increasing expenses and operating losses for the foreseeable future as it advances product candidates through preclinical and clinical development, seeks regulatory approval, and expands its intellectual property portfolio. It anticipates needing substantial additional funding to support continuing operations and growth strategy, as current cash is not sufficient for at least one year. The company plans to finance operations through public or private equity/debt offerings or collaboration agreements. An IND for a Phase I trial for CLD-401 (RedTail platform) is expected to be filed by the end of 2026.

Management Comments

• "We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public company."
• "We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates."
• "Based on our operating plan, we believe we do not have sufficient cash on hand to support current operations for at least one year from the date of issuance of our unaudited condensed consolidated financial statements as of, and for the three and nine months ended September 30, 2025."
• "We have concluded that this circumstance raises substantial doubt about our ability to continue as a going concern."
• "We believe that RedTail, given its systemic administration and targeting to metastatic sites and its delivery of genetic medicines, represents a major advancement in the space of oncolytic virus in oncology."

Industry Context

Calidi Biotherapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, focusing on genetic medicines and oncolytic viruses for cancer therapy. The industry is characterized by long development cycles, high regulatory hurdles, and significant R&D expenses. The company's strategy of using stem cell-based and engineered enveloped viruses to overcome immune clearance challenges in oncolytic virotherapy addresses a key limitation in the field, as evidenced by the limited success of existing therapies like T-VEC for metastatic disease. The Fast Track Designation for CLD-201 highlights the potential unmet medical need it aims to address, aligning with broader industry trends towards accelerated pathways for promising therapies. However, the company's ongoing losses and going concern warning are typical for early-stage biotech firms that have not yet commercialized products, underscoring the inherent risks in this sector.

Comparison to Industry Standards

• The company's accumulated deficit of $137.6 million and recurring net losses are common for clinical-stage biotechnology companies that are pre-revenue and heavily investing in research and development, similar to many peers in the oncology drug development space.
• The increase in cash from financing activities ($17.1 million in 9M 2025 vs. $14.3 million in 9M 2024) demonstrates an ability to attract capital, which is crucial for biotech companies, though the 'going concern' warning indicates this is a continuous challenge.
• The 1-for-12 reverse stock split in August 2025, following a 1-for-10 split in July 2024, suggests the company's stock price has been under significant pressure, a common occurrence for small-cap biotechs facing clinical development risks and funding challenges, often done to maintain listing requirements on exchanges like NYSE American.
• The Fast Track Designation for CLD-201 for soft tissue sarcoma is a positive regulatory milestone, comparable to similar designations received by other biotech companies for drug candidates addressing serious conditions with unmet needs, potentially offering advantages in development and review timelines.
• The company's R&D expenses increasing by 4% while G&A expenses decreased by 21% for the nine months ended September 30, 2025, indicates a focus on core drug development activities while attempting to control administrative overhead, a prudent approach for a company in its stage, aligning with best practices for resource allocation in early-stage biotech.

Management Changes

Corporate Governance

Legal Proceedings

• Lawsuit by former Chief Accounting Officer and interim Chief Financial Officer, Tony Kalajian, alleging defamation and constructive discharge, with the company initiating arbitration for breach of fiduciary duty.
• Lawsuit by former Controller, Hazel Sanchez, alleging defamation, constructive discharge, violation of California Family Rights Act, and wrongful discharge, with the company filing a cross-complaint for breach of fiduciary duty.
• Lawsuit by Mr. Kalajian alleging intentional conversion and violation of Delaware General Corporations Code Section 158 due to failure to remove a restrictive legend from shares, consolidated with the primary case.
• Lawsuit filed by the company against a former executive assistant alleging breach of fiduciary duty, constructive fraud, conversion, and misappropriation of confidential information.
• Securities fraud complaint filed by Mr. Yian Zeng against the company in US District Court, Southern District of California, alleging violations of California Corporations Code 25401, breach of covenant of good faith and fair dealing, unjust enrichment, restitution, breach of fiduciary duty, and constructive fraud. A mandatory settlement conference resulted in no resolution, and a final pre-trial conference is set for April 9, 2026.

Related Party Transactions

• Related party term notes payable, net of discount, including accrued interest, totaling $405,000 due to Director A and Director E as of September 30, 2025.
• Accounts payable and accrued expenses of $11,000 owed to Director F and a relative of Officer A as of September 30, 2025.
• Severance accrual of $344,000 for Director F as of September 30, 2025.
• Lease guaranty provided by Director F for the San Diego Lease, with a present value of $9,000 payment due to Director F as of September 30, 2025.
• Warrant liability of $15,000 related to Director F and Director A as of September 30, 2025.
• Severance accrual of $179,000 for Officer G as of September 30, 2025.
• Severance accrual of $249,000 for Officer A as of September 30, 2025.
• Strategic investment of approximately $2.0 million by a related-party accredited investor into Nova Cell on July 26, 2024, for 25% of Nova Cell's fully-diluted capitalization.
• Sale of 75% ownership interest in Nova Cell to Nova Cell on October 27, 2025, for $6.0 million, satisfied in part by cancellation of $1.2 million indebtedness and $4.8 million deferred consideration, plus an ongoing royalty.

Stakeholder Impact

• **Shareholders**: Significant dilution from recent and potential future equity raises, coupled with two reverse stock splits, negatively impacts per-share value. The 'going concern' warning poses a substantial risk to investment value. Legal proceedings could further erode shareholder value.
• **Employees**: Management changes, including the elimination of executive positions and associated severance packages, may impact employee morale and organizational stability. Stock-based compensation plans are in place, but the overall financial health could affect their value.
• **Customers/Patients**: The progress in product candidates, including Fast Track Designation for CLD-201, offers potential future benefits for patients with conditions like soft tissue sarcoma, but the long development cycles and funding uncertainties mean these benefits are not immediate.
• **Suppliers/Creditors**: The company's 'going concern' status and reliance on future financing could pose risks to suppliers and creditors regarding timely payments, although current liabilities have decreased. The sale of Nova Cell involved debt cancellation, which is positive for some creditors.
• **Regulatory Authorities**: The company continues to engage with regulatory bodies, as evidenced by the Fast Track Designation, indicating ongoing compliance and development efforts.

Next Steps

• File an IND for a Phase I trial for CLD-401 (RedTail platform) by the end of 2026.
• Continue research and development efforts for current and future product candidates.
• Initiate clinical trials for product candidates.
• Seek marketing approval for product candidates.
• Manufacture drug product and drug supply.
• Maintain and expand the intellectual property portfolio.
• Hire additional research and development and business personnel.
• Obtain substantial additional funding through public/private equity or debt financing, or collaboration agreements.
• Defend against ongoing legal proceedings, including a securities fraud case with a final pre-trial conference set for April 9, 2026.

Key Dates

Recommendation

Calidi Biotherapeutics presents a high-risk investment profile. The explicit 'substantial doubt about our ability to continue as a going concern' is a critical red flag, indicating severe financial distress despite recent capital raises. While the Fast Track Designation for CLD-201 is a positive clinical development, it does not offset the fundamental liquidity and operational risks. The company's history of two reverse stock splits and increasing net loss attributable to common stockholders (due to deemed dividends on warrants) points to significant shareholder dilution and a deteriorating equity value. Multiple ongoing legal proceedings add further uncertainty and potential financial burden. The company's reliance on continuous capital raises in a volatile market, coupled with its pre-revenue stage, makes it highly speculative. A seasoned investor would view the 'going concern' warning as a primary driver for a 'strong sell' recommendation, prioritizing capital preservation over the speculative upside of early-stage biotech.

Keywords

Biotechnology, Oncolytic Virus, Genetic Medicines, Cancer Therapy, Clinical Stage, SEC Filing, 10-Q, Financial Results, Liquidity, Going Concern, Capital Raise, Reverse Stock Split, FDA Fast Track, Soft Tissue Sarcoma, Research and Development, Warrants, Nova Cell, Legal Proceedings